Biotech Values

[bladerunner1717]

Cantor Fitzgerald raises price target on CLDX to $13


Celldex Therapeutics (NASDAQ: CLDX) had its target price lifted by Cantor Fitzgerald from $9.00 to $13.00 in a report issued on Thursday. They currently have a buy rating on the stock.

A number of other firms have also recently commented on CLDX. Analysts at Oppenheimer raised their price target on shares of Celldex Therapeutics to $10.00 in a research note to investors on Monday, December 10th. Finally, analysts at Brean Murray reiterated a buy rating on shares of Celldex Therapeutics in a research note to investors on Monday, December 10th. They now have a $14.00 price target on the stock.

Shares of Celldex Therapeutics opened at 7.31 on Thursday. Celldex Therapeutics has a 52 week low of $3.07 and a 52 week high of $7.38. The stock’s 50-day moving average is currently $6.45. The company’s market cap is $453.0 million.

Bladerunner